ArticleBlood advances2022

Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition.

Tim Kong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.